Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Leuprorelin added to finasteride and tamsulosin for acute urinary retention due to BPH
IRCT20170417033489N3Phase 3Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Nov 2019
- Modality
- Small Molecules, Peptides
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in benign prostatic hyperplasia (BPH) comparing Leuprorelin + finasteride + tamsulosin with Finasteride + tamsulosin (2 arms). Primary endpoint: Release from catheterization one month after acute urinary retention. Started Nov 2019; status: completed.
02
Drugs
leuprolidefinasteridetamsulosin
03
Conditions
benign prostatic hyperplasia (BPH)
Beyond the preview
Go deeper on IRCT20170417033489N3.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20170417033489N3.